Peru's Auna Q3 revenue rises on growth across markets

By Reuters News


Overview

  • Peru-based healthcare platform's Q3 revenue rose 10% FX-neutral, driven by growth in all markets

  • Q3 adjusted EBITDA declined 5% FX-neutral, with margin at 17.5%

  • Profitability pressured by higher costs in Colombia and Peru, partly offset by Mexico recovery


Outlook

  • Auna reaffirms full-year 2026 revenue guidance for FX-neutral growth of 10% to 14%

  • Company expects full-year 2026 Adjusted EBITDA to be broadly stable or slightly down year-over-year

  • Auna maintains capital expenditures guidance at about 4% of revenues for 2026


Result Drivers

  • MEXICO RECOVERY - Segment adjusted EBITDA in Mexico grew year-over-year, driven by higher surgical and oncology volumes and improved capacity utilization at the Monterrey Healthcare network, partly offset by weaker results at Auna Seguros

  • COLOMBIA PROFITABILITY PRESSURE - Adjusted EBITDA in Colombia declined due to extraordinary adverse medical costs under a specific oncology risk-sharing contract, regulatory price caps on high-cost oncology medications, and higher personnel costs

  • PERU COST IMPACTS - Profitability in Peru was affected by penalties from reconciliation of prior years’ receivables and higher pharmacy and clinical payroll costs associated with increased patient volumes


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Adjusted EBITDA Margin

17.50%


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 4 three months ago


Reuters Recommended Reads

  • Nov 17 - France's Alstom posts first-half loss on setbacks in German rail project


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.